Sulfur In R Patents (Class 514/618)
  • Patent number: 10233201
    Abstract: Compounds and compositions are provided that inhibit histone deacylase activity and which expand renal progenitor cell populations and improve kidney function in a damaged kidney. Methods of use of the compounds and compositions are provided.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: March 19, 2019
    Assignee: University of Pittsburg—Of the Commonwealth System of Higher Education
    Inventors: Neil Hukriede, Billy W. Day, Lee A. McDermott
  • Patent number: 9782367
    Abstract: The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by a support appearing as granules. Said fluid may be CO2 or another solvent and the support, anhydrous lactose or mannitol. Application of the pharmaceutical composition in the cases when increased short term alertness and over a short period is required for the consumer of the pharmaceutical composition.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: October 10, 2017
    Assignee: DEBREGEAS ET ASSOCIES PHARMA
    Inventors: Christophe Lebon, Pascal Suplie, Fabrice Leboeuf, Jennifer Jung, Frantz Deschamps
  • Patent number: 9770454
    Abstract: The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
    Type: Grant
    Filed: July 13, 2014
    Date of Patent: September 26, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Hadas Reuveni, Ehud Cohen, Alexander Levitzki, Shmuel Ben-Sasson
  • Patent number: 9637447
    Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: May 2, 2017
    Assignee: NLS Pharma AG
    Inventor: Eric Konofal
  • Patent number: 9248116
    Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 2, 2016
    Assignee: NEWRON PHARMACEUTICALS S.P.A.
    Inventors: Piero Melloni, Alessandra Restivo, Emanuela Izzo, Simona Francisconi, Elena Colombo, Cibele Sabido-David
  • Patent number: 9084719
    Abstract: Novel formulations containing a fluorinated chloramphenicol or thiamphenicol derivative antibiotic such as florfenicol, and methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: July 21, 2015
    Assignee: Intervet Inc.
    Inventors: Keith A. Freehauf, Allan Weingarten, Robert D. Simmons, Kanwal Jit Varma
  • Publication number: 20150141513
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological degenerative disorders and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of narcolepsy, shift work sleep disorder, and as an adjunct treatment for obstructive sleep apnea/hypopnea, hypersomnias, like idiopathic hypersomnia, Psychiatric/neurodegenerative disorders, ADHD, Psychiatric/neurodegenerative disorders, Depersonalization disorder, Cognitive enhancement, Fatigue, Post-chemotherapy cognitive impairment and weight loss.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 21, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150126531
    Abstract: A pharmaceutical composition is provided which includes a pharmaceutically acceptable excipient and a pharmaceutically and physically acceptable amount of a compound selected from the group consisting of Chemical Formulas I-IV as described herein, or a pharmaceutically acceptable salt thereof. Also provided are methods of increasing a level of a defined neurotrophic peptide in an organism or tissue comprising the administration of a pharmaceutically and physically acceptable amount of one or more of the compositions described above, and a method for treating a neurodegenerative disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 7, 2015
    Applicant: Saint Louis College of Pharmacy
    Inventor: John M. Beale
  • Publication number: 20150125389
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
    Type: Application
    Filed: September 9, 2014
    Publication date: May 7, 2015
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Raymond John Andersen, Carmen Adriana Banuelos, Javier GARCIA FERNANDEZ, Yusuke IMAMURA, Jian KUNZHONG, Nasrin R. MAWJI, Marianne Dorothy Sadar, Jun Wang, Amy (Hsing Chen) Tien
  • Publication number: 20150118300
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: July 17, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118301
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 4, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118295
    Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
    Type: Application
    Filed: September 12, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150118302
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Publication number: 20150105470
    Abstract: The present invention relates to a novel method for obtaining a pharmaceutical composition based on modafinil. This method consists of solubilizing S modafinil in a fluid in the supercritical state and then after expansion of said fluid, recovering S modafinil by causing it to be absorbed at the surface by a support appearing as granules. Said fluid may be CO2 or another solvent and the support, anhydrous lactose or mannitol. Application of the pharmaceutical composition in the cases when increased short term alertness and over a short period is required for the consumer of the pharmaceutical composition.
    Type: Application
    Filed: February 25, 2013
    Publication date: April 16, 2015
    Inventors: Christophe Lebon, Pascal Suplie, Fabrice Leboeuf, Jennifer Jung, Frantz Deschamps
  • Publication number: 20150094276
    Abstract: This invention relates to novel substituted styryl benzylsulfones that are multikinase inhibitors and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an agent that inhibits kinases, such as phosphatidylinositol 3-kinase (PI3-K) and polo-like kinase (PLK-1).
    Type: Application
    Filed: April 19, 2013
    Publication date: April 2, 2015
    Inventor: Roger D. Tung
  • Publication number: 20150073055
    Abstract: The present invention relates to the application of modafinil in cocaine addiction. The modafinil used is its dextro-rotatory enantiomer (S modafinil), having a release time of less than 1 hour and wakening effect of less than 4 hours. It is absorbed orally as a pharmaceutical composition, each unit dose including from 25 to 200 mg of S modafinil. The pharmaceutical composition can be used as a substitute treatment for cocaine addicts.
    Type: Application
    Filed: February 25, 2013
    Publication date: March 12, 2015
    Applicant: DEBREGEAS ET ASSOCIES PHARMA
    Inventors: Pascal Suplie, Philippe Vivet
  • Publication number: 20150051290
    Abstract: The present invention relates to kinase inhibitors for the treatment of cancer. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of cancer.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 19, 2015
    Applicant: PITNEY PHARMACEUTICALS PTY LIMITED
    Inventor: David Lawson Morris
  • Publication number: 20150045367
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: December 19, 2012
    Publication date: February 12, 2015
    Inventors: Erik Verner, Wei Chen, Sriram Balasubramanian
  • Publication number: 20150011516
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
  • Patent number: 8927606
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: January 6, 2015
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Publication number: 20140323423
    Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: Chrono Therapeutics, Inc.
    Inventors: Guy DiPierro, Steven A. Giannos
  • Patent number: 8871749
    Abstract: Provided is a bone-transplant or bone-filling composition, which comprises a dihydroxybenzoic acid derivative which has been newly demonstrated to increase the activity of osteoblasts and so induce bone formation.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: October 28, 2014
    Assignee: Cellsafe Co., Ltd.
    Inventor: Jae-Jin Han
  • Patent number: 8871813
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: October 28, 2014
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Patent number: 8859560
    Abstract: The present invention relates to a method of treating attention deficit hyperactivity disorder in a subject. This method includes selecting a subject with attention deficit hyperactivity disorder and administering to the selected subject a sodium/hydrogen exchanger inhibitor under conditions effective to treat the subject for attention deficit hyperactivity disorder. Methods of identifying compounds suitable to treat attention deficit hyperactivity disorder are also disclosed.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: October 14, 2014
    Assignee: The Research Foundation of State University of New York
    Inventor: Stephen V. Faraone
  • Patent number: 8859621
    Abstract: Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: October 14, 2014
    Assignee: Cephalon, Inc.
    Inventors: Craig S. Heacock, Alpa B. Parikh, Piyush R. Patel
  • Patent number: 8853281
    Abstract: Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are H, halo, C1-C4alkyl, C1-C4haloalkyl, C1-C4alkoxy; or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10alkyl chain, C2-C4haloalkyl or C3-C7cycloalkylmethyl, R4 is Het, Carbocyclyl, optionally substituted as defined in the specification and pharmaceutically acceptable salts, hydrates and N-oxides thereof; are inhibitors of cathepsin S and have utility in the treatment of psoriasis, autoimmune disorders and other disorders such as asthma, arteriosclerosis, COPD and chronic pain.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: October 7, 2014
    Assignee: Medivir UK Ltd
    Inventors: Susana Ayesa, Anna Karin Belfrage, Bjorn Classon, Urszula Grabowska, Ellen Hewitt, Vladimir Ivanov, Daniel Jönsson, Pia Kahnberg, Peter Lind, Magnus Nilsson, Lourdes Odén, Mikael Pelcman, Horst Wähling
  • Publication number: 20140296333
    Abstract: The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.
    Type: Application
    Filed: October 24, 2012
    Publication date: October 2, 2014
    Applicant: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION
    Inventors: Suk Hyo Suh, Jae Chul Jung, Sei Kwan Oh
  • Publication number: 20140256743
    Abstract: This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicants: Merck Frosst Canada Ltd., Axys Pharmaceuticals, Inc.
    Inventors: Christopher I. Bayly, Cameron Black, Serge Leger, Chun Sing Li, Dan McKay, Christophe Mellon, Jacques Yves Gauthier, Vouy-Linh Truong, Cheuk Lau, Michel Therien, Michael J. Green, Bernard L. Hirschbein, James William Janc, James T. Palmer, Chitra I. Baskaran
  • Publication number: 20140235702
    Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having sulfonamido-1-hydroxynaphthalene structure which function as inhibitors of Mcl-1 protein, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: October 8, 2012
    Publication date: August 21, 2014
    Inventors: Zaneta Nikolovska-Coleska, Hollis D. Showalter, Chenzhong Liao, Ramzi Mohammad, Fardokht Abulwerdi
  • Patent number: 8809586
    Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: August 19, 2014
    Assignee: Cephalon, Inc.
    Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
  • Patent number: 8791162
    Abstract: This invention relates to deuterated compounds which are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 29, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kelem Kassahun, Christine Fandozzi, Donald R. Gauthier, Jr., Lisa A. Shipley
  • Patent number: 8754131
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: June 17, 2014
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Publication number: 20140155383
    Abstract: The present invention relates to the use of cathepsin K and/or cathepsin S inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.
    Type: Application
    Filed: May 11, 2012
    Publication date: June 5, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stefan Golz, Martina Delbeck, Heinrich Meier, Andreas Geerts, Thomas Mondritzki, Hubert Trübel
  • Publication number: 20140148468
    Abstract: The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.
    Type: Application
    Filed: November 27, 2013
    Publication date: May 29, 2014
    Applicant: GRÜNENTHAL GMBH
    Inventors: Simon LUCAS, Sven Kühnert, Gregor Bahrenberg, Wolfgang Schröder
  • Patent number: 8729305
    Abstract: The invention relates to a polymorphic form of (?)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 14.14, 10.66, 7.80 and 4.02 ?, and a process for the preparation thereof.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: May 20, 2014
    Assignee: Teva Sante
    Inventors: Pierre Leproust, Olivier Neckebrock
  • Patent number: 8716343
    Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: May 6, 2014
    Assignee: Regents of the University of Minnesota
    Inventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
  • Publication number: 20140113898
    Abstract: The invention relates to bisarylsulfone and dialkylarylsulfone compounds (e.g., compounds according to any of Formulas (I)-(IX) or compounds (1)-(227) of Tables 4 and 5) useful in treating conditions associated with calcium channel function, and particularly conditions associated with N-type calcium channel activity. The invention also relates to pharmaceutical compositions that include these bisarylsulfone compounds, as well methods for the treatment of conditions such as cardiovascular disease, epilepsy, cancer and pain.
    Type: Application
    Filed: November 4, 2011
    Publication date: April 24, 2014
    Applicant: Zalicus Pharmaceuticals Ltd.
    Inventors: Hassan A. Pajouhesh, Richard Holland, Yuanxi Zhou, Yongbao Zhu, Michael Edward Grimwood, Navjot Chahal
  • Publication number: 20140105908
    Abstract: Disclosed herein are methods and compositions for reducing the recurrence of prostate cancer and for treating prostate cancer.
    Type: Application
    Filed: May 3, 2012
    Publication date: April 17, 2014
    Applicant: UNIVERSITY OF ROCHESTER
    Inventor: Chawnshang Chang
  • Patent number: 8686047
    Abstract: Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: April 1, 2014
    Assignee: Cephalon, Inc.
    Inventors: Craig S. Heacock, Alpa B. Parikh, Piyush R. Patel
  • Publication number: 20140088157
    Abstract: Provided are an endoparasite control agent comprising a carboxamide derivative represented by the general formula (I): or a salt thereof as an active ingredient, and a method for controlling endoparasites, comprising orally or parenterally administering the endoparasite control agent.
    Type: Application
    Filed: March 1, 2012
    Publication date: March 27, 2014
    Applicants: NIHON NOHYAKU CO., LTD., THE UNIVERSITY OF TOKYO
    Inventors: Kiyoshi Kita, Akiyuki Suwa
  • Patent number: 8680154
    Abstract: Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 25, 2014
    Assignee: Intervet International B.V.
    Inventor: Carole Barbot
  • Publication number: 20140073562
    Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
    Type: Application
    Filed: March 15, 2012
    Publication date: March 13, 2014
    Applicant: OPTINOSE AS
    Inventor: Per Gisle Djupesland
  • Patent number: 8669290
    Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: March 11, 2014
    Assignee: Senju Pharmaceutical Co., Ltd.
    Inventors: Shirou Sawa, Shuhei Fujita
  • Patent number: 8653134
    Abstract: Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: February 18, 2014
    Assignee: Merck Patent GmbH
    Inventors: Catherine Vidal, Nathalie Adje, Stéphane Yvon, Jean Jacques Zeiller
  • Patent number: 8642656
    Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: February 4, 2014
    Assignee: Regents of the University of Minnesota
    Inventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
  • Patent number: 8642799
    Abstract: Several parasites responsible for mammalian diseases are dependent on cysteine protease for various life-cycle functions. Inhibition or decreasing function of these proteases can be useful in the treatment and/or prevention of these parasitic diseases including; toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, schistosomiasis, amebiasis, giardiasis, clonorchiasis, opisthorchiasis, paragonimiasis, fasciolopsiasis, lymphatic filariasis, onchocerciasis, dracunculiasis, ascariasis, trichuriasis, stronglyoidiasis, trichostrongyliasis, trichomoniasis or cestodiasis.
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: February 4, 2014
    Assignee: Merck Canada Inc.
    Inventors: Elise Isabel, Christopher Mellon, Christian Beaulieu
  • Publication number: 20140024679
    Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: December 31, 2012
    Publication date: January 23, 2014
    Applicant: Reviva Pharmaceuticals, Inc.
    Inventor: Reviva Pharmaceuticals, Inc.
  • Patent number: 8629274
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 14, 2014
    Assignee: Novira Therapeutics, Inc.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Publication number: 20130338231
    Abstract: The invention provides compound of the general formula: in which each X independently represents a polymer chain; n represents an integer greater than 1; Q represents a linker; Y represents an amide group; and Z represents either —CH.(CH2L)2 or —C(CH2L)(?CH2), in which each L independently represents a leaving group. The compounds are useful reagents for the conjugation of polymers to proteins, the resulting conjugates being novel and also forming part of the invention.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 19, 2013
    Inventors: Antony GODWIN, Stephen Brocchini
  • Publication number: 20130324508
    Abstract: The present invention relates to a biomarker for characterizing prostate cancer and method of using the same. More particularly, the invention relates to method of using a membrane-associated C family G protein-coupled receptor GPRC6A as biomarker of characterizing prostate cancer progression. The present invention also provides a kit for detecting prostate cancer in a subject.
    Type: Application
    Filed: June 3, 2013
    Publication date: December 5, 2013
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Leigh Darryl Quarles, Min Pi